299 related articles for article (PubMed ID: 24418414)
1. Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer.
Thangapazham R; Saenz F; Katta S; Mohamed AA; Tan SH; Petrovics G; Srivastava S; Dobi A
BMC Cancer; 2014 Jan; 14():16. PubMed ID: 24418414
[TBL] [Abstract][Full Text] [Related]
2. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
Linn DE; Bronson RT; Li Z
PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
[TBL] [Abstract][Full Text] [Related]
3. NKX3.1 Suppresses TMPRSS2-ERG Gene Rearrangement and Mediates Repair of Androgen Receptor-Induced DNA Damage.
Bowen C; Zheng T; Gelmann EP
Cancer Res; 2015 Jul; 75(13):2686-98. PubMed ID: 25977336
[TBL] [Abstract][Full Text] [Related]
4. Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.
Todorova K; Metodiev MV; Metodieva G; Mincheff M; Fernández N; Hayrabedyan S
Horm Cancer; 2017 Feb; 8(1):28-48. PubMed ID: 28050800
[TBL] [Abstract][Full Text] [Related]
5. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
6. TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c.
Kim J; Wu L; Zhao JC; Jin HJ; Yu J
Oncogene; 2014 Oct; 33(44):5183-92. PubMed ID: 24186205
[TBL] [Abstract][Full Text] [Related]
7. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
[TBL] [Abstract][Full Text] [Related]
8. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion.
Gerashchenko GV; Mevs LV; Chashchina LI; Pikul MV; Gryzodub OP; Stakhovsky EO; Kashuba VI
Exp Oncol; 2018 Jun; 40(2):101-108. PubMed ID: 29949537
[TBL] [Abstract][Full Text] [Related]
9. An NKX3.1 binding site polymorphism in the l-plastin promoter leads to differential gene expression in human prostate cancer.
Chen C; Cai Q; He W; Li Z; Zhou F; Liu Z; Zhong G; Chen X; Zhao Y; Dong W; Huang J; Zheng J; Lin T
Int J Cancer; 2016 Jan; 138(1):74-86. PubMed ID: 26148677
[TBL] [Abstract][Full Text] [Related]
10. Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.
Yin L; Rao P; Elson P; Wang J; Ittmann M; Heston WD
PLoS One; 2011; 6(6):e21319. PubMed ID: 21731703
[TBL] [Abstract][Full Text] [Related]
11. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.
Setlur SR; Mertz KD; Hoshida Y; Demichelis F; Lupien M; Perner S; Sboner A; Pawitan Y; Andrén O; Johnson LA; Tang J; Adami HO; Calza S; Chinnaiyan AM; Rhodes D; Tomlins S; Fall K; Mucci LA; Kantoff PW; Stampfer MJ; Andersson SO; Varenhorst E; Johansson JE; Brown M; Golub TR; Rubin MA
J Natl Cancer Inst; 2008 Jun; 100(11):815-25. PubMed ID: 18505969
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions.
Singareddy R; Semaan L; Conley-Lacomb MK; St John J; Powell K; Iyer M; Smith D; Heilbrun LK; Shi D; Sakr W; Cher ML; Chinni SR
Mol Cancer Res; 2013 Nov; 11(11):1349-61. PubMed ID: 23918819
[TBL] [Abstract][Full Text] [Related]
13. TMPRSS2-ERG fusion protein regulates insulin-like growth factor-1 receptor (IGF1R) gene expression in prostate cancer: involvement of transcription factor Sp1.
Meisel Sharon S; Pozniak Y; Geiger T; Werner H
Oncotarget; 2016 Aug; 7(32):51375-51392. PubMed ID: 27285981
[TBL] [Abstract][Full Text] [Related]
14. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.
Sandoval GJ; Pulice JL; Pakula H; Schenone M; Takeda DY; Pop M; Boulay G; Williamson KE; McBride MJ; Pan J; St Pierre R; Hartman E; Garraway LA; Carr SA; Rivera MN; Li Z; Ronco L; Hahn WC; Kadoch C
Mol Cell; 2018 Aug; 71(4):554-566.e7. PubMed ID: 30078722
[TBL] [Abstract][Full Text] [Related]
15. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues.
Tu JJ; Rohan S; Kao J; Kitabayashi N; Mathew S; Chen YT
Mod Pathol; 2007 Sep; 20(9):921-8. PubMed ID: 17632455
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M; Lissbrant E; Damber JE; Stenman G
Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
[TBL] [Abstract][Full Text] [Related]
17. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
[TBL] [Abstract][Full Text] [Related]
18. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
Pflueger D; Rickman DS; Sboner A; Perner S; LaFargue CJ; Svensson MA; Moss BJ; Kitabayashi N; Pan Y; de la Taille A; Kuefer R; Tewari AK; Demichelis F; Chee MS; Gerstein MB; Rubin MA
Neoplasia; 2009 Aug; 11(8):804-11. PubMed ID: 19649210
[TBL] [Abstract][Full Text] [Related]
19. Characterization of two functional NKX3.1 binding sites upstream of the PCAN1 gene that are involved in the positive regulation of PCAN1 gene transcription.
Liu W; Zhang P; Chen W; Yu C; Cui F; Kong F; Zhang J; Jiang A
BMC Mol Biol; 2008 May; 9():45. PubMed ID: 18454873
[TBL] [Abstract][Full Text] [Related]
20. TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases.
Delliaux C; Tian TV; Bouchet M; Fradet A; Vanpouille N; Flourens A; Deplus R; Villers A; Leroy X; Clézardin P; de Launoit Y; Bonnelye E; Duterque-Coquillaud M
Cancer Lett; 2018 Dec; 438():32-43. PubMed ID: 30201302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
